NY-AQARA
13.9.2022 09:01:43 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, introduced its Radiator Thermostat E1 to automate hydronic radiators including wall-mounted radiators, towel warmers and even warm floors, making the heating systems smarter for improved energy efficiency and comfort. This radiator thermostat supports most radiator valves with its M30*1.5mm thread connection and the provided adapters for RA, RAV and RAVL valves1. The Aqara Radiator Thermostat E1 is now available on European Amazon stores (France, Germany, Italy, Spain, UK), as well as via selective Aqara retailers in Europe2.
Based on the Zigbee 3.0 protocol, the Thermostat is expected to support the future-proofing Matter standard via an OTA update of the compatible, Zigbee 3.0-based Aqara hub3. The device is also compatible with major ecosystems and voice assistants such as HomeKit/Siri, Alexa, Google Home/Google Assistant, IFTTT, Home Assistant4 and more. Users can be reassured that the Thermostat works with their smart home setups of today and tomorrow.
Unlike many thermostatic radiator valves (TRVs) that rely solely on an internal sensor to measure the room temperature, which can be inaccurate due to the sensor’s proximity to the radiator, the Radiator Thermostat E1 can receive the temperature readings directly from a connected Aqara temperature sensor5 (including in HomeKit), and regulate the radiator based on the actual room temperature to increase comfort. Moreover, when connected to an Aqara Door and Window Sensor, the Thermostat can be configured to stop heating the room when any door or window is left open, in order to reduce energy waste. With the wide range of Aqara devices, users are able to create customized home automation that heats their homes only when it’s needed.
The Aqara Home app also offers various options for radiator automation. A smart schedule can be configured, allowing users to set the desired temperatures for different periods of time throughout the day, for example to set it to 5℃ during the daytime of weekdays when no one is at home, 25℃ for a relaxing evening after work, and 20℃ for a night of comfortable sleep. Geofencing is also possible, so the radiators will heat up the home before the family arrives. Another option is to automate the radiators based on local weather, and the heating will turn on automatically when the local temperature drops below a certain threshold.
Other features of the Radiator Thermostat include:
- Device grouping: multiple radiators in one room can be synchronized so that they work in a more efficient way, and make it possible to set different temperatures for each room;
- Multi-home management: in the case of having more than one home, users are able to manage the radiators in each home separately and set up individual automation such as geofencing-based automation;
- Anti-freeze mode: users can preset a temperature between 5℃ - 15℃ for this mode, and activate the mode easily when they are out of town to conserve energy while reducing the risk of pipe freezing;
- 12-month battery life: thanks to the Zigbee protocol and the energy-efficient hardware, 2 AA batteries will power the Thermostat for up to one year of use6.
To celebrate the launch, Aqara now offers a 10% discount for the Radiator Thermostat on its European Amazon stores in France, Germany, Italy, Spain and the UK with the promo code TRVE1UKEU. The code will be valid through September 15, 2022.
For more details of the Radiator Thermostat E1, please visit our website.
- This thermostat is only compatible with thermostatic valves, while manual, return temperature limiter (RTL) as well as monotube radiator systems are not supported. However in the majority of cases, it is possible to convert the existing radiator valve to a supporting one using an aftermarket adapter. Please consult professional installers or authorized Aqara retailers for more details.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the local retailer(s) for real time availability.
- Matter support may be unavailable by the time of the launch.
- Home Assistant support can be achieved using HomeKit Controller integration, which is developed by the Home Assistant community.
- Aqara’s Temperature and Humidity Sensor or TVOC Air Quality Monitor is required.
- Battery life may vary depending on the usage. The 1-year battery life is calculated based on the assumption of 8 operations per day for a heating season of 165 days and 1 operation every 2 weeks for the rest 200 days.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
